Mounjaro (Tirzepatide) in Adults 65 and Older: Dosing and Safety

Does the dose change for adults 65 and older?

No. The Mounjaro dosing section starts adults at 2.5 mg subcutaneously once weekly and raises the dose in 2.5 mg increments after at least 4 weeks on the current dose if more glycemic control is needed; the adult maximum is 15 mg weekly [1]. It draws no line by age, and there is no dose adjustment for renal or hepatic impairment [1].

A missed dose can be given within 4 days (96 hours); after that it is skipped and the regular day resumes [1]. The weekly day can be changed as long as two doses are at least 3 days (72 hours) apart, and injections go into the abdomen, thigh, or back of the upper arm (that site by another person), rotating sites each time [1].

Mounjaro is indicated for glycemic control in type 2 diabetes, in adults and in children 10 and older, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them [1]. It is not labeled for weight loss; weight management and obstructive sleep apnea are Zepbound indications [1].

Two contraindications apply at any age: a personal or family history of medullary thyroid carcinoma or MEN 2, and a known serious hypersensitivity to tirzepatide or an excipient [1]. The boxed warning describes thyroid C-cell tumors in rats at clinically relevant exposures and states that human relevance, including medullary thyroid carcinoma, is unknown [1]. Routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection [1].

How much of the trial evidence comes from people over 65?

The label's pooled safety data show who was studied. The pool of two placebo-controlled trials (SURPASS-1 and SURPASS-5) included 718 adults treated with Mounjaro, with a mean age of 58, and 4% were 75 or older [1]. The larger pool of seven controlled trials included 5,119 adults treated with Mounjaro, again with a mean age of 58 and 4% aged 75 or older [1].

The cardiovascular outcomes trial had an older population: 13,165 adults with type 2 diabetes and atherosclerotic cardiovascular disease, mean age 64.1 [3]. The SURMOUNT-1 body-composition substudy ran post hoc subgroup analyses by age band (under 50, 50 to under 65, and 65 and older) [2].

Gastrointestinal side effects and kidney risk

In the label's pooled placebo-controlled trials in adults with type 2 diabetes (235 on placebo; 237, 240 and 241 on 5, 10 and 15 mg; mean exposure 36.6 weeks), nausea occurred in 4% on placebo versus 12%, 15% and 18% on 5, 10 and 15 mg [1]. Diarrhea ran 9% versus 12%, 13% and 17%; vomiting 2% versus 5%, 5% and 9%; decreased appetite 1% versus 5%, 10% and 11%; and constipation 1% versus 6%, 6% and 7% [1].

Gastrointestinal adverse reactions overall were reported by 20.4% of placebo patients versus 37.1%, 39.6% and 43.6% on the three doses, and 0.4% versus 3.0%, 5.4% and 6.6% stopped treatment because of them [1]. Most reports of nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. Mounjaro is not recommended in patients with severe gastroparesis [1].

The label describes postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Mounjaro; most reported events occurred in patients with gastrointestinal reactions that led to dehydration, such as nausea, vomiting or diarrhea [1]. It says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

Hypoglycemia with insulin or a sulfonylurea

The Mounjaro label states that combining it with an insulin secretagogue such as a sulfonylurea, or with insulin, may increase the risk of hypoglycemia including severe hypoglycemia, and that reducing the dose of the sulfonylurea or insulin may lower that risk [1]. The drug interactions section says to consider reducing the dose of the insulin secretagogue or insulin when Mounjaro is started [1].

For a sense of scale, the Zepbound label reports that in SURMOUNT-2, a weight-management trial in adults with type 2 diabetes, hypoglycemia below 54 mg/dL occurred in 10.3% of participants taking a sulfonylurea versus 2.1% of those not taking one.

What happens to lean mass during weight loss

The body-composition substudy of SURMOUNT-1 (adults with obesity or overweight, without diabetes) is the most direct evidence here: 160 participants had DXA scans at baseline and at week 72, 124 pooled across tirzepatide doses and 36 on placebo, 73% female, mean weight 102.5 kg and BMI 38.0 [2]. Body weight fell 21.3% on tirzepatide versus 5.3% on placebo, fat mass fell 33.9% versus 8.2%, and lean mass fell 10.9% versus 2.6% (p<0.001 for each comparison) [2].

Of the weight lost, roughly 75% was fat mass and about 25% lean mass, the same split in both the tirzepatide and placebo groups, and those proportions remained consistent across most post hoc subgroup analyses, which included age bands [2]. The substudy is small, and DXA does not separate muscle from other lean tissue [2].

The Zepbound label says tirzepatide lowers body weight with greater fat mass loss than lean mass loss, and gives no lean-mass numbers.

Heart risk: the indication and the outcomes trial

Mounjaro is indicated to reduce the risk of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke in adults with type 2 diabetes at high risk for these events [1]. The cardiovascular outcomes trial, SURPASS-CVOT, was double-blind and compared tirzepatide up to 15 mg with dulaglutide 1.5 mg in 13,165 adults with type 2 diabetes and atherosclerotic cardiovascular disease, mean age 64.1 [3]. The composite of cardiovascular death, myocardial infarction or stroke occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide: hazard ratio 0.92, 95.3% CI 0.83 to 1.01, noninferiority met (p=0.003) and superiority not met (p=0.09) [3].

That is a noninferiority result against an active comparator, not a comparison with placebo.

Pens, vision, and the caregiver question

The label tells prescribers to specify which presentation the patient will receive (vial, prefilled single-dose pen or single-patient-use KwikPen), to train the patient and any caregiver on that specific presentation, and to retrain if the presentation changes [1]. It states that the KwikPen is not recommended for self-administration by people who are visually impaired, and that a KwikPen must never be shared between patients even if the needle is changed [1].

The label also notes that pulmonary aspiration has been reported in patients receiving GLP-1 receptor agonists who underwent elective surgery or procedures with general anesthesia or deep sedation, and it instructs patients to inform health care providers of any planned surgery or procedure [1].

What is not known

A 2024 review of obesity drug treatment in older adults notes that concise guidelines for older adults are not available and that more trials are needed with geriatric endpoints such as muscle mass preservation and bone quality [4]. The age-based body-composition findings above come from a post hoc analysis of 160 people [2].